Exact Sciences' Stock Offers A 'Good Entry Point,' This Bullish Analyst Says
Portfolio Pulse from Priya Nigam
Shares of Exact Sciences Corp (NASDAQ:EXAS) were climbing ahead of the company’s Q3 earnings call. Piper Sandler analyst David Westenberg upgraded the rating for Exact Sciences from Neutral to Overweight, while keeping the price target unchanged at $90. Westenberg cited strong Cologuard growth and a clear path to maintaining growth rates above 10% for more than five years as reasons for the upgrade.
October 10, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences Corp's stock has been upgraded by Piper Sandler analyst David Westenberg from Neutral to Overweight. The price target remains unchanged at $90.
The upgrade from Piper Sandler is a positive signal for the stock. The analyst cites strong growth of Cologuard and a clear path to maintaining growth rates above 10% for more than five years as reasons for the upgrade. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100